Reversion of KPC-114 to KPC-2 in ceftazidime-avibactam- resistant/meropenem-susceptible Klebsiella pneumoniae ST11 is related to low mutation rates
Microbiology Spectrum · 2024
DOI: 10.1128/spectrum.01173-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2024. Verfasst von Jesus G M Pariona und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Analysis, Faculty of Pharmaceutical Sciences, Universidade de São Paulo, São Paulo, Brazil. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Ceftazidime, Azabicyclo Compounds, beta-Lactamases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Agencia Nacional de Investigación y Desarrollo (ANID).
Abstract (Originalsprache)
Klebsiella pneumoniae strains that produce Klebsiella pneumoniae Carbapenemase (KPC) variants displaying resistance to ceftazidime-avibactam (CZA) often remain susceptible to meropenem (MEM), suggesting a potential therapeutic use of this carbapenem antibiotic. However, in vitro studies indicate that these sorts of strains can mutate becoming MEM-resistant, raising concerns about the effectiveness of carbapenems as treatment option. We have studied mutation rates occurring from the reversion of MEM-susceptible KPC-114 to MEM-resistant KPC-2, in CZA-resistant K. pneumoniae belonging to ST11. Two-step fluctuation assays (FAs) were conducted. In brief, initial cultures of KPC-114-producing K. pneumoniae showing 1 µg/mL MEM MIC were spread on Mueller–Hinton agar plates containing 2–8 µg/mL MEM. A second step of FA, at 4–16 µg/mL MEM was performed from a mutant colony obtained at 2 µg/mL MEM. Mutation rates were calculated using maximum likelihood estimation. Parental and mutant strains were sequenced by Illumina NextSeq, and mutations were predicted by variant-calling analysis. At 8 µg/mL MEM, mutants derived from parental CZA-resistant (MIC ≥ 64 µg/mL)/MEM-susceptible (MIC = 1 µg/mL) KPC-114-positive K. pneumoniae exhibited an accumulative mutation rate of 3.05 × 10 −19 mutations/cell/generation, whereas at 16 µg/mL MEM an accumulative mutation rate of 1.33 × 10 −19 mutations/cell/generation resulted in the reversion of KPC-114 (S181_P182 deletion) to KPC-2. These findings highlight that the reversion of MEM-susceptible KPC-114 to MEM-resistant KPC-2, in CZA-resistant K. pneumoniae ST11 is related to low mutation rates suggesting a low risk of therapeutic failure. In vivo investigations are necessary to confirm the clinical potential of MEM against CZA-resistant KPC variants. IMPORTANCE The emergence of ceftazidime-avibactam (CZA) resistance among carbapenem-resistant Klebsiella pneumoniae is a major concern due to the limited therapeutic options. Strikingly, KPC mutations mediating CZA resistance are generally associated with meropenem susceptibility, suggesting a potential therapeutic use of this carbapenem antibiotic. However, the reversion of meropenem-susceptible to meropenem-resistant could be expected. Therefore, knowing the mutation rate related to this genetic event is essential to estimate the potential use of meropenem against CZA-resistant KPC-producing K. pneumoniae . In this study, we demonstrate, in vitro , that under high concentrations of meropenem, reversion of KPC-114 to KPC-2 in CZA-resistant/meropenem-susceptible K. pneumoniae belonging to the global high-risk ST11 is related to low mutation rates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Analysis, Faculty of Pharmaceutical Sciences, Universidade de São Paulo, São Paulo, Brazil.
- One Health Brazilian Resistance Project (OneBR), São Paulo, Brazil.
- Department of Microbiology, Instituto de Ciências Biomédicas II, Universidade de São Paulo, São Paulo, Brazil.
- Antimicrobial Resistance Institute of São Paulo (ARIES), São Paulo, Brazil.
- Universidad Peruana Cayetano Heredia, Unidad de Investigación de Enfermedades Emergentes y Cambio Climático, San Martín de Porres, Peru.
- Escola Politécnica, Engenharia Elétrica, Universidade de São Paulo, São Paulo, Brazil.
ORCID-Profile: Jesus G M Pariona, Felipe Vásquez-Ponce, Jorge L Mello Sampaio, Rodrigo S Galhardo, Nilton Lincopan
Förderung
- Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
- Agencia Nacional de Investigación y Desarrollo (ANID)
Zitieren
APA
Pariona, J. G. M., Vásquez-Ponce, F., Becerra, J., Martins-Gonçalves, T., Pariona, E. M. M., Madueño, F. T., Esposito, F., V de Lima, A., Mello Sampaio, J. L., Galhardo, R. S., & Lincopan, N. (2024). Reversion of KPC-114 to KPC-2 in ceftazidime-avibactam- resistant/meropenem-susceptible Klebsiella pneumoniae ST11 is related to low mutation rates. Microbiology Spectrum. https://doi.org/10.1128/spectrum.01173-24
Vancouver
Pariona JGM, Vásquez-Ponce F, Becerra J, Martins-Gonçalves T, Pariona EMM, Madueño FT, et al. Reversion of KPC-114 to KPC-2 in ceftazidime-avibactam- resistant/meropenem-susceptible Klebsiella pneumoniae ST11 is related to low mutation rates. Microbiology Spectrum. 2024. doi:10.1128/spectrum.01173-24
BibTeX
@article{Pariona2024,
author = {Pariona, Jesus G M and Vásquez-Ponce, Felipe and Becerra, Johana and Martins-Gonçalves, Thais and Pariona, Eva M M and Madueño, Fabio T and Esposito, Fernanda and V de Lima, Aline and Mello Sampaio, Jorge L and Galhardo, Rodrigo S and Lincopan, Nilton},
title = {Reversion of KPC-114 to KPC-2 in ceftazidime-avibactam- resistant/meropenem-susceptible Klebsiella pneumoniae ST11 is related to low mutation rates},
journal = {Microbiology Spectrum},
year = {2024},
doi = {10.1128/spectrum.01173-24}
}
EUVIMED